Impact of Pre-procedure Cognitive Status on Outcome at 3 Months After Transcatheter Aortic Valve Implantation
- Conditions
- Aortic Stenosis
- Interventions
- Other: MoCA cognitive assessment
- Registration Number
- NCT04564534
- Lead Sponsor
- Centre Hospitalier Universitaire de Besancon
- Brief Summary
This study plans to investigate the relationship between cognitive status pre-procedure, and clinical outcomes at 3 months in patients undergoing transcatheter aortic valve implantation (TAVI).
- Detailed Description
This study plans to investigate the relationship between cognitive status pre-procedure, as assessed using the Montreal Cognitive Assessment (MoCA) administered on a tablet, and clinical outcomes at 3 months as assessed by the VARC2 criteria, in patients undergoing transcatheter aortic valve implantation (TAVI)
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 109
- Aged 18 years or over
- Scheduled to undergo TAVI
- Provide informed consent
- Able to understand French
- subjects under legal guardianship or other legal protection
- subjects with documented severe dementia
- subjects with anticipated poor compliance
- subjects unable to understand French sufficiently well to perform the MoCA test
- pregnant women
- subjects within the exclusion period of another study
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Study cohort MoCA cognitive assessment Adult (\>18 years) patients with aortic stenosis in whom TAVI is planned and who perform their pre-TAVI work-up in our centre will be invited to undergo cognitive assessment using the MoCA at the time of their hospitalization for pre-TAVI work-up. The MoCA will be administered by trained professionals with MoCA certification. Clinical outcomes, as assessed by the VARC2 criteria, will be collected for all patients at 3 months after the TAVI procedure.
- Primary Outcome Measures
Name Time Method Stroke through 30 days after the TAVI procedure Safety outcome at 30 days as assessed by the VARC2 criteria: stroke
All-cause death through 30 days after the TAVI procedure Safety outcome at 3 months as assessed by the VARC2 criteria: all-cause death
life-threatening bleed through 30 days after the TAVI procedure Safety outcome at 30 days as assessed by the VARC2 criteria: life-threatening bleed
Combined VARC2 safety outcome through 30 days after the TAVI procedure Safety criteria (within 30 days of the procedure) include all-cause death; stroke; life-threatening bleed; renal insufficiency; coronary artery obstruction requiring intervention; major vascular complication; valve dysfunction.
Clinical Efficacy criteria (30 days to 3 months after the procedure) include: all-cause death; stroke; re-admission for valve-relaCombined VARC2 efficacy outcome through 30 days after the TAVI procedure Clinical Efficacy criteria (30 days to 3 months after the procedure) include: all-cause death; stroke; re-admission for valve-related symptoms or worsening heart failure; NYHA Class III or IV; valve-related dysfunction.
- Secondary Outcome Measures
Name Time Method Time required for MoCA At the time of MoCA completion Length of time required to administer the MoCA test using a tablet
Relationship between MoCA score and each component of the VARC2 At 3 months after TAVI procedure The relationship between the MoCA and each individual component of the VARC2 will be investigated in bivariable analysis.
Biological parameters pre-procedure pre-procedure Blood count; prothrombin; TCA; fibrinogen; INR; creatinine; CRP; BNP; TSH; HbA1c; troponin; albumin; GDF15.
Trial Locations
- Locations (1)
University Hospital Jean Minjoz
🇫🇷Besancon, France